[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 430
1. Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, Falotico N, Leverson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H, Letai A: Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov; 2016 10;6(10):1106-1117
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.
  • We present a phase II, single-arm study evaluating 800 mg daily venetoclax, a highly selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor in patients with high-risk relapsed/refractory acute myelogenous leukemia (AML) or unfit for intensive chemotherapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Bridged Bicyclo Compounds, Heterocyclic / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Sulfonamides / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome. Young Adult


2. Ponce DM, Hilden P, Devlin SM, Maloy M, Lubin M, Castro-Malaspina H, Dahi P, Hsu K, Jakubowski AA, Kernan NA, Koehne G, O'Reilly RJ, Papadopoulos EB, Perales MA, Sauter C, Scaradavou A, Tamari R, van den Brink MR, Young JW, Giralt S, Barker JN: High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia. Biol Blood Marrow Transplant; 2015 Nov;21(11):1985-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia.
  • Double-unit cord blood (DCB) grafts are a rapidly available stem cell source for adults with high-risk leukemias.
  • We analyzed 166 allograft recipients (66 8/8 HLA-matched URDT, 45 7/8 HLA-matched URDT, and 55 DCBT) ages 16 to 60 years with high-risk acute leukemia or chronic myelogenous leukemia (CML).
  • All URDT recipients received a CD34(+) cell-selected (T cell-depleted) graft.
  • In multivariate analysis in acute leukemia patients, factors adversely associated with DFS were female gender (hazard ratio [HR], 1.68; P = .031), diagnosis of acute lymphoblastic leukemia (HR, 2.09; P = .004), and 7/8 T cell-depleted URDT (HR, 1.91; P = .037).
  • High DFS can be achieved in adults with acute leukemia and CML with low relapse rates after DCBT.
  • Our findings support performing DCBT in adults in preference to HLA-mismatched T cell-depleted URDT and suggest DCBT is a readily available alternative to T cell-depleted 8/8 URDT, especially in patients requiring urgent transplantation.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Myeloablative Agonists / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Female. Graft Survival. Histocompatibility Testing. Humans. Lymphocyte Depletion. Male. Middle Aged. Recurrence. Retrospective Studies. Sex Factors. Survival Analysis. T-Lymphocytes / cytology. T-Lymphocytes / immunology. Transplantation, Homologous. Unrelated Donors

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, T-cell, chronic.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] Immunol Lett. 2013 Sep-Oct;155(1-2):31-5 [24120996.001]
  • [Cites] Blood. 2014 Jan 2;123(1):133-40 [24141369.001]
  • [Cites] Bone Marrow Transplant. 2014 Jan;49(1):122-5 [24037024.001]
  • [Cites] Haematologica. 2014 Mar;99(3):535-40 [24143000.001]
  • [Cites] Biol Blood Marrow Transplant. 2014 Jun;20(6):787-93 [24548875.001]
  • [Cites] Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):34-8 [24602918.001]
  • [Cites] J Clin Invest. 2014 Jul;124(7):3121-8 [24911148.001]
  • [Cites] N Engl J Med. 2014 Jul 24;371(4):339-48 [25054717.001]
  • [Cites] Bone Marrow Transplant. 2014 Sep;49(9):1184-6 [25000459.001]
  • [Cites] Blood. 2014 Nov 6;124(19):2905-12 [25185264.001]
  • [Cites] Blood. 2015 Jan 1;125(1):199-205 [25377785.001]
  • [Cites] Biol Blood Marrow Transplant. 2015 May;21(5):926-33 [25655791.001]
  • [Cites] Biol Blood Marrow Transplant. 2015 May;21(5):920-5 [25687796.001]
  • [Cites] Leuk Lymphoma. 2015 Jun;56(6):1799-805 [25224458.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):855-64 [9217189.001]
  • [Cites] Blood. 1998 Feb 1;91(3):1083-90 [9446672.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1343-7 [15466923.001]
  • [Cites] Lancet. 2005 Aug 27-Sep 2;366(9487):733-41 [16125590.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2912-9 [15994282.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56 [16338616.001]
  • [Cites] Stat Med. 2007 Oct 30;26(24):4505-19 [17348080.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Oct;13(10):1145-52 [17889350.001]
  • [Cites] Blood. 2007 Oct 15;110(8):3064-70 [17569820.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Dec;13(12):1469-76 [18022577.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4552-9 [17717135.001]
  • [Cites] J Clin Oncol. 2009 Jan 10;27(2):256-63 [19064984.001]
  • [Cites] Bone Marrow Transplant. 2009 Mar;43(5):365-73 [18850019.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2410-5 [18997171.001]
  • [Cites] Stat Med. 2009 Aug 30;28(19):2473-89 [19472308.001]
  • [Cites] Blood. 2009 Nov 5;114(19):4293-9 [19706886.001]
  • [Cites] Nat Med. 2010 Feb;16(2):232-6 [20081862.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Nov;16(11):1541-8 [20800103.001]
  • [Cites] Blood. 2010 Nov 25;116(22):4693-9 [20686119.001]
  • [Cites] Blood. 2011 Feb 24;117(8):2332-9 [21149636.001]
  • [Cites] Blood. 2011 Mar 24;117(12):3277-85; quiz 3478 [21149633.001]
  • [Cites] Biol Blood Marrow Transplant. 2011 Sep;17(9):1335-42 [21232623.001]
  • [Cites] Biol Blood Marrow Transplant. 2011 Sep;17(9):1316-26 [21232625.001]
  • [Cites] Blood. 2011 Nov 17;118(20):5689-96 [21937692.001]
  • [Cites] Leuk Lymphoma. 2012 May;53(5):901-6 [21988645.001]
  • [Cites] Blood. 2012 Jun 7;119(23):5591-8 [22496153.001]
  • [Cites] Bone Marrow Transplant. 2012 Jul;47(7):924-33 [22002488.001]
  • [Cites] J Clin Oncol. 2012 Sep 10;30(26):3194-201 [22869882.001]
  • [Cites] Blood. 2012 Dec 6;120(24):4882-91 [23012326.001]
  • [Cites] N Engl J Med. 2012 Dec 13;367(24):2305-15 [23234514.001]
  • [Cites] Biol Blood Marrow Transplant. 2013 Feb;19(2):208-13 [22982534.001]
  • [Cites] Blood. 2013 Jan 31;121(5):752-8 [23223509.001]
  • [Cites] Biol Blood Marrow Transplant. 2013 May;19(5):682-91 [23142329.001]
  • [Cites] Biol Blood Marrow Transplant. 2013 May;19(5):799-803 [23416850.001]
  • [Cites] Biol Blood Marrow Transplant. 2013 Jun;19(6):904-11 [23416854.001]
  • [Cites] Biol Blood Marrow Transplant. 2013 Jun;19(6):898-903 [23467126.001]
  • [Cites] Bone Marrow Transplant. 2013 Jun;48(6):782-6 [23241738.001]
  • [Cites] Biol Blood Marrow Transplant. 2013 Sep;19(9):1355-60 [23791622.001]
  • [Cites] Blood. 2013 Oct 24;122(17):3074-81 [23996087.001]
  • (PMID = 26238810.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA023766; United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / P01 CA23766
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloablative Agonists
  • [Other-IDs] NLM/ NIHMS712626 [Available on 11/01/16]; NLM/ PMC4768474 [Available on 11/01/16]
  • [Keywords] NOTNLM ; Acute leukemia / Cord blood transplantation / HLA match / Unrelated donor transplantation
  •  go-up   go-down


3. Lee EJ, Smith BD, Merrey JW, Lee AI, Podoltsev NA, Barbarotta L, Litzow MR, Prebet T, Luger SM, Gore S, Streiff MB, Zeidan AM: Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey. Clin Lymphoma Myeloma Leuk; 2015 Dec;15(12):766-770
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey.
  • BACKGROUND: Venous thromboembolism (VTE) occurs in 2% to 12% of patients with acute leukemia (AL) despite disease- and therapy-associated thrombocytopenia, and it can be associated with significant morbidity and mortality.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2015 Elsevier Inc. All rights reserved.
  • [Cites] Blood. 2009 Apr 23;113(17):3911-7 [19088376.001]
  • [Cites] J Clin Oncol. 2009 Oct 10;27(29):4848-57 [19752334.001]
  • [Cites] Thromb Res. 2010 Apr;125 Suppl 2:S96-102 [20434017.001]
  • [Cites] Curr Opin Oncol. 2012 Nov;24(6):702-10 [23014188.001]
  • [Cites] Thromb Res. 2013 Nov;132(5):511-4 [24090605.001]
  • [Cites] Cancer Med. 2015 Jan;4(1):27-35 [25487644.001]
  • [Cites] Thromb Res. 2005;115(1-2):59-64 [15567454.001]
  • [Cites] N Engl J Med. 2003 Jul 10;349(2):146-53 [12853587.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):811-7 [15953009.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4063-9 [15767639.001]
  • [Cites] J Thromb Haemost. 2005 Sep;3(9):1985-92 [16102104.001]
  • [Cites] Acta Haematol. 2007;117(4):215-20 [17237616.001]
  • [Cites] J Thromb Haemost. 2007 Sep;5(9):1878-82 [17723127.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2007;:165-71 [18024625.001]
  • [Cites] Thromb Res. 2007;120 Suppl 2:S99-106 [18023721.001]
  • (PMID = 26363982.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA180826; United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / U10 CA180802; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / CA180820; United States / NCI NIH HHS / CA / CA180802; United States / NCI NIH HHS / CA / CA180826; United States / NCI NIH HHS / CA / U10 CA180790; United States / NCI NIH HHS / CA / U10 CA180820; United States / NCI NIH HHS / CA / CA180790
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrinolytic Agents
  • [Other-IDs] NLM/ NIHMS737838; NLM/ PMC4663156
  • [Keywords] NOTNLM ; Acute leukemia / Acute lymphoid leukemia / Acute myeloid leukemia / Deep venous thrombosis / Patterns of practice
  •  go-up   go-down


Advertisement
4. Kanakry JA, Kasamon YL, Gocke CD, Tsai HL, Davis-Sproul J, Ghosh N, Symons H, Bolaños-Meade J, Gladstone DE, Swinnen LJ, Luznik L, Fuchs EJ, Jones RJ, Ambinder RF: Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant; 2013 Apr;19(4):602-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma.
  • The role of allogeneic blood or marrow transplantation (alloBMT) for peripheral T cell lymphoma (PTCL) remains to be defined.
  • On unadjusted landmark analysis, patients with acute grade II-IV or chronic graft-versus-host disease (GVHD) had a 17% probability of relapse (95% CI, 0% to 39%), compared with 66% (95% CI, 48% to 84%) in patients without GVHD, P = .04.
  • [MeSH-major] Bone Marrow Transplantation / immunology. Graft vs Host Disease / immunology. HLA Antigens / immunology. Lymphoma, T-Cell, Peripheral / therapy. Myeloablative Agonists / therapeutic use. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Aged. Female. Histocompatibility Testing. Humans. Longitudinal Studies. Male. Middle Aged. Remission Induction. Secondary Prevention. Survival Analysis. Transplantation, Homologous. Unrelated Donors

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] Curr Opin Hematol. 2010 Nov;17(6):493-9 [20827187.001]
  • [Cites] Blood. 2010 Aug 26;116(8):1369-76 [20479287.001]
  • [Cites] Blood. 2011 May 12;117(19):5019-32 [21300984.001]
  • [Cites] Ann Oncol. 2011 Jul;22(7):1608-13 [21252059.001]
  • [Cites] Leuk Lymphoma. 2011 Aug;52(8):1463-73 [21699453.001]
  • [Cites] Leukemia. 2012 Mar;26(3):520-6 [21904377.001]
  • [Cites] Leuk Lymphoma. 2012 Jun;53(6):1124-9 [22136377.001]
  • [Cites] J Clin Oncol. 2012 Sep 1;30(25):3093-9 [22851556.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(7):377-86 [12171484.001]
  • [Cites] Am J Med. 1980 Aug;69(2):204-17 [6996481.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):561-7 [16098071.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56 [16338616.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1533-8 [16871285.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Apr;14(4):480-3 [18342792.001]
  • [Cites] Ann Oncol. 2008 May;19(5):958-63 [18303032.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2264-71 [18390969.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jun;14(6):641-50 [18489989.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Br J Haematol. 2008 Sep;142(5):848-50 [18631344.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Nov;14(11):1279-87 [18940683.001]
  • [Cites] J Clin Oncol. 2009 Jan 1;27(1):106-13 [19029417.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 May;15(5):547-53 [19361746.001]
  • [Cites] J Clin Oncol. 2009 Aug 20;27(24):3951-8 [19620487.001]
  • [Cites] Biom J. 2010 Feb;52(1):138-58 [20029852.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Apr;16(4):482-9 [19925877.001]
  • [Cites] Blood. 2010 Apr 22;115(16):3224-30 [20124511.001]
  • [Cites] Blood. 2011 Mar 24;117(12):3402-8 [21270441.001]
  • (PMID = 23370119.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / Myeloablative Agonists
  • [Other-IDs] NLM/ NIHMS560625; NLM/ PMC4020434
  •  go-up   go-down


5. Baron F, Suciu S, Amadori S, Muus P, Zwierzina H, Denzlinger C, Delforge M, Thyss A, Selleslag D, Indrak K, Ossenkoppele G, de Witte T: Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group. Haematologica; 2012 Apr;97(4):529-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group.
  • Forty-six patients with myelodysplastic syndromes and a relatively low risk of developing acute leukemia were included in a randomized phase II study assessing the therapeutic activity of two dosages of infliximab administration (3 mg/kg vs. 5 mg/kg).

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Infliximab .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Dec 4;354(9194):1932-9 [10622295.001]
  • [Cites] Br J Haematol. 2010 Jun;149(5):706-10 [20331464.001]
  • [Cites] Br J Haematol. 2000 Sep;110(3):620-30 [10997974.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3671-4 [11090046.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1098-104 [11596589.001]
  • [Cites] Leukemia. 2002 Feb;16(2):162-4 [11840280.001]
  • [Cites] Br J Haematol. 2002 Feb;116(2):334-7 [11841434.001]
  • [Cites] Lancet. 2002 May 4;359(9317):1541-9 [12047962.001]
  • [Cites] Leuk Lymphoma. 2004 Oct;45(10):2099-104 [15370256.001]
  • [Cites] Biometrics. 1984 Sep;40(3):587-600 [6394062.001]
  • [Cites] Leukemia. 1992 Dec;6(12):1268-72 [1280751.001]
  • [Cites] Haematologica. 1994 May-Jun;79(3):265-8 [7926977.001]
  • [Cites] Blood. 1995 Jul 1;86(1):268-76 [7795232.001]
  • [Cites] J Cell Physiol. 1995 Dec;165(3):538-46 [7593233.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]
  • [Cites] Clin Lab Haematol. 1997 Sep;19(3):197-201 [9352145.001]
  • [Cites] Br J Haematol. 1998 Oct;103(1):176-88 [9792306.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3917-25 [16105982.001]
  • [Cites] Blood. 2008 Jan 1;111(1):86-93 [17893227.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2505-11 [18413642.001]
  • [Cites] Annu Rev Med. 2010;61:345-58 [20059342.001]
  • [Cites] Br J Haematol. 2010 Mar;148(6):944-7 [20064151.001]
  • [CommentIn] Haematologica. 2012 Aug;97(8):e26; author reply e27 [22855845.001]
  • (PMID = 22102701.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5U10 CA11488-32; United States / NCI NIH HHS / CA / 5U10 CA11488-38; United States / NCI NIH HHS / CA / 5U10 CA11488-39; United States / NCI NIH HHS / CA / 5U10 CA11488-35; United States / NCI NIH HHS / CA / 5U10 CA11488-37; United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / 2U10 CA011488-40; United States / NCI NIH HHS / CA / 2U10 CA011488-41; United States / NCI NIH HHS / CA / 5U10 CA11488-36; United States / NCI NIH HHS / CA / 5U10 CA11488-33; United States / NCI NIH HHS / CA / 5U10 CA11488-34
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab
  • [Other-IDs] NLM/ PMC3347667
  •  go-up   go-down


6. Kantarjian HM, Lioure B, Kim SK, Atallah E, Leguay T, Kelly K, Marolleau JP, Escoffre-Barbe M, Thomas XG, Cortes J, Jabbour E, O'Brien S, Bories P, Oprea C, Hatteville L, Dombret H: A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk; 2016 Mar;16(3):139-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.
  • BACKGROUND: Long-term disease-free survival in adult patients with acute lymphoblastic leukemia (ALL) remains unsatisfactory, and the treatment options are limited for those patients with relapse or a failure to respond after initial therapy.
  • [MeSH-major] Antibodies, Monoclonal, Humanized / therapeutic use. Antineoplastic Agents / therapeutic use. Immunotoxins / therapeutic use. Maytansine / analogs & derivatives. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • HAL archives ouvertes. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 Elsevier Inc. All rights reserved.
  • [Cites] Leuk Lymphoma. 2011 Feb;52(2):325-7 [21077738.001]
  • [Cites] Clin Cancer Res. 2013 Apr 1;19(7):1795-805 [23426279.001]
  • [Cites] J Clin Oncol. 2014 Dec 20;32(36):4134-40 [25385737.001]
  • [Cites] Stat Med. 2005 Jul 30;24(14):2171-81 [15909289.001]
  • [Cites] Cancer. 2010 Mar 1;116(5):1165-76 [20101737.001]
  • [Cites] Clin Cancer Res. 2014 Jan 1;20(1):213-20 [24132920.001]
  • [Cites] Clin Cancer Res. 2011 Oct 15;17(20):6448-58 [22003072.001]
  • [Cites] Leukemia. 2015 Mar;29(3):526-34 [25079173.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Cancer Manag Res. 2013 Aug 27;5:225-33 [24023523.001]
  • [Cites] Lancet Oncol. 2015 Jan;16(1):57-66 [25524800.001]
  • (PMID = 26775883.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Immunotoxins; 0 / SAR 3419; 14083FR882 / Maytansine
  • [Keywords] NOTNLM ; Adult / Antibody-drug conjugate / CD19 / Maytansine derivatives / Safety
  •  go-up   go-down


7. Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, Bosworth A, Francisco L, He J, Bansal A, Morgan EA, Lacasce AS, Freedman AS, Fisher DC, Jacobsen E, Armand P, Alyea EP, Koreth J, Ho V, Soiffer RJ, Antin JH, Ritz J, Nikiforow S, Forman SJ, Michor F, Neuberg D, Bhatia R, Bhatia S, Ebert BL: Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol; 2017 May 10;35(14):1598-1605
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.
  • We hypothesized that in patients undergoing autologous stem-cell transplantation (ASCT) for lymphoma, CHIP at the time of ASCT would be associated with an increased risk of myelodysplastic syndrome and acute myeloid leukemia, collectively termed therapy-related myeloid neoplasm (TMN), and other adverse outcomes.
  • Methods We performed whole-exome sequencing on pre- and post-ASCT samples from 12 patients who developed TMN after autologous transplantation for Hodgkin lymphoma or non-Hodgkin lymphoma and targeted sequencing on cryopreserved aliquots of autologous stem-cell products from 401 patients who underwent ASCT for non-Hodgkin lymphoma between 2003 and 2010.
  • Conclusion In patients undergoing ASCT for lymphoma, CHIP at the time of transplantation is associated with inferior survival and increased risk of TMN.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Hodgkin Disease / therapy. Leukemia, Myeloid, Acute / etiology. Lymphoma, Non-Hodgkin / therapy. Myelodysplastic Syndromes / etiology. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Clone Cells. DNA (Cytosine-5-)-Methyltransferase / genetics. DNA Mutational Analysis. DNA-Binding Proteins / genetics. Exome. Female. Hematopoiesis. Humans. Male. Middle Aged. Protein Phosphatase 2C / genetics. Proto-Oncogene Proteins / genetics. Repressor Proteins / genetics. Survival Rate. Transplantation, Autologous / adverse effects. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2015 Feb 26;125(9):1367-76 [25550361.001]
  • [Cites] Nat Commun. 2016 Aug 22;7:12484 [27546487.001]
  • [Cites] Nature. 2015 Feb 26;518(7540):552-5 [25487151.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2472-81 [11331326.001]
  • [Cites] N Engl J Med. 2014 Dec 25;371(26):2477-87 [25426838.001]
  • [Cites] Blood. 2015 Jul 2;126(1):9-16 [25931582.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4215-22 [15701723.001]
  • [Cites] J Natl Cancer Inst. 2016 Jan 27;108(3): [26823519.001]
  • [Cites] Oncogene. 2007 Mar 1;26(10 ):1449-58 [16936775.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3128-35 [10506609.001]
  • [Cites] JAMA Oncol. 2016 Mar;2(3):370-2 [26847329.001]
  • [Cites] Ann Hematol. 2002 Jan;81(1):11-5 [11807629.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4496-503 [9616144.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1840-7 [16932351.001]
  • [Cites] Blood. 2003 Jul 1;102(1):43-52 [12623843.001]
  • [Cites] Nat Med. 2014 Dec;20(12):1472-8 [25326804.001]
  • [Cites] Nature. 2013 Jan 17;493(7432):406-10 [23242139.001]
  • [Cites] Cancer Cell. 2007 Oct;12 (4):342-54 [17936559.001]
  • [Cites] Blood. 1988 Oct;72(4):1333-9 [3167210.001]
  • [Cites] Cell Rep. 2015 Mar 3;10 (8):1239-45 [25732814.001]
  • [Cites] N Engl J Med. 2014 Dec 25;371(26):2488-98 [25426837.001]
  • [Cites] Br J Cancer. 2015 Mar 17;112(6):1114-20 [25742468.001]
  • [Cites] Blood. 2011 Feb 17;117(7):2137-45 [21127174.001]
  • (PMID = 28068180.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R24 DK099808; United States / NCI NIH HHS / CA / K08 CA204734; United States / NHLBI NIH HHS / HL / R01 HL082945; United States / NHLBI NIH HHS / HL / T32 HL116324; United States / NCI NIH HHS / CA / P30 CA006516; United States / NCI NIH HHS / CA / P50 CA107399
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ASXL1 protein, human; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; 0 / TET2 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA methyltransferase 3A; EC 3.1.3.16 / PPM1D protein, human; EC 3.1.3.16 / Protein Phosphatase 2C
  •  go-up   go-down


8. De Keersmaecker K, Atak ZK, Li N, Vicente C, Patchett S, Girardi T, Gianfelici V, Geerdens E, Clappier E, Porcu M, Lahortiga I, Lucà R, Yan J, Hulselmans G, Vranckx H, Vandepoel R, Sweron B, Jacobs K, Mentens N, Wlodarska I, Cauwelier B, Cloos J, Soulier J, Uyttebroeck A, Bagni C, Hassan BA, Vandenberghe P, Johnson AW, Aerts S, Cools J: Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet; 2013 Feb;45(2):186-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia.
  • T-cell acute lymphoblastic leukemia (T-ALL) is caused by the cooperation of multiple oncogenic lesions.
  • We detected protein-altering mutations in 508 genes, with an average of 8.2 mutations in pediatric and 21.0 mutations in adult T-ALL.
  • We identify CNOT3 as a tumor suppressor mutated in 7 of 89 (7.9%) adult T-ALLs, and its knockdown causes tumors in a sensitized Drosophila melanogaster model.
  • Our data provide insights into the mutational landscape of pediatric versus adult T-ALL and identify the ribosome as a potential oncogenic factor.
  • [MeSH-major] Exome / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Ribosomal Proteins / genetics. Transcription Factors / genetics


9. Rogers HJ, Vardiman JW, Anastasi J, Raca G, Savage NM, Cherry AM, Arber D, Moore E, Morrissette JJ, Bagg A, Liu YC, Mathew S, Orazi A, Lin P, Wang SA, Bueso-Ramos CE, Foucar K, Hasserjian RP, Tiu RV, Karafa M, Hsi ED: Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica; 2014 May;99(5):821-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
  • Acute myeloid leukemia and myelodysplastic syndrome with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) have a poor prognosis.
  • However, inv(3)(q21q26.2)/t(3;3)(q21;q26.2) is not among the cytogenetic abnormalities pathognomonic for diagnosis of acute myeloid leukemia irrespective of blast percentage in the 2008 WHO classification.
  • This multicenter study evaluated the clinico-pathological features of acute myeloid leukemia/myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and applied the revised International Prognostic Scoring System to myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2).
  • A total of 103 inv(3)(q21q26.2)/t(3;3)(q21;q26.2) patients were reviewed and had a median bone marrow blast count of 4% in myelodysplastic syndrome (n=40) and 52% in acute myeloid leukemia (n=63) (P<0.001).
  • There was no difference in overall survival between acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) (12.9 vs. 7.9 months; P=0.16).
  • Our data support consideration of myelodysplastic syndrome with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) as an acute myeloid leukemia with recurrent genetic abnormalities, irrespective of blast percentage.
  • [MeSH-major] Abnormal Karyotype. Bone Marrow / pathology. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology. Myelodysplastic Syndromes / genetics. Myelodysplastic Syndromes / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Inversion. Chromosomes, Human, Pair 3. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Patient Outcome Assessment. Prognosis. Translocation, Genetic. Young Adult


10. Zeichner SB, Arellano ML: Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process. Curr Treat Options Oncol; 2015 Aug;16(8):37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process.
  • With the recent understanding that the secondary nature of sAML does not by itself incur a poor prognosis and incorporation of cytogenetics and molecular genetics into patient care and the advancement of treatment, including improved supportive care, novel chemotherapeutics agents, and nonmyeloablative conditioning regimens as part of allogeneic hematopoietic cell transplantation (HCT), modest gains in survival and quality of life are beginning to be seen among patients with s-AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / therapy. Neoplasms, Second Primary
  • [MeSH-minor] Adult. Humans. Prognosis. Risk






Advertisement